KalVista Pharmaceuticals KALV 深 沪
等待开盘 08-30 09:30:00 美东时间
13.46
-0.050
-0.37%
华盛通- 最 高13.78
- 今 开13.50
- 成交量 43.65万股
- 最 低 13.23
- 昨 收 13.51
- 总市值 6.72亿
- 52周最高 16.32
- 市盈率 静 --
- 换手率 0.87%
- 52周最低 7.30
- 委 比 -61.65%
- 总股本 4995.37万
- 历史最高 45.00
- 量 比 0.79
- 振 幅 4.07%
- 历史最低 4.12
- 每 手 1
- 风险率 1.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Going On With Takeda Stock On Friday?
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.
08-22 23:21
KalVista Pharmaceuticals Updates Stockholder Meeting Schedule
KalVista Pharmaceuticals ( ($KALV) ) just unveiled an announcement. KalVista Ph...
08-22 05:31
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
08-22 02:24
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
Metagenomi, a precision genetic medicines company, has appointed Laurence Reid, PhD, to its Board of Directors. With 30 years of experience in biotech, Dr. Reid brings expertise in company building, R&D strategy, and organizational growth. His加入将助力Metagenomi advance its gene editing technologies and deliver curative genetic medicines for patients. The company leverages AI and machine learning to develop next-generation genome editing therapies ta...
08-11 20:05
KalVista Pharmaceuticals Maintains EU Orphan Designation For Sebetralstat, Securing Potential 10 Years Of Market Exclusivity Upon Approval
Sebetralstat is one of only two hereditary angioedema therapies to maintain orphan designation, underscoring its major contribution to patient careIf approved, sebetralstat will be granted 10 years of market exclusivity
08-11 19:16
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista Pharmaceuticals (NASDAQ:KALV), Biogen (NASDAQ:BIIB), and Ionis Pharmaceuticals (NASDAQ:IONS) announced that the European Medicines Agency (EMA) has given positive endorsements for their produ...
07-25 21:23
KalVista gets UK nod for Ekterly
KalVista Pharmaceuticals (NASDAQ:KALV) said that the UK health regulator has granted marketing authorization for Ekterly (sebetralstat), a plasma inhibitor, to treat hereditary angioedema attacks in p...
07-16 04:44
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
07-14 20:14
国投证券-生物医药行业新药周观点：创新药5月进院数据更新，多个新纳入医保创新药快速进院中-250713
（转自：研报虎） 本周新药行情回顾： 2025年7月7日-2025年7月13日，新药板块涨幅前5企业：北海康成(114.5%)、前沿生物(41.4%)、君...
07-13 21:23
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $27 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $27 price target.
07-11 18:19
